Sarah E. Smith-Jeffcoat

Sarah E. Smith-Jeffcoat

Auto-generated profile, based on publicly available information

Sarah E. Smith-Jeffcoat

Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
SSSarah E. Smith-Jeffcoat
Sarah E. Smith-Jeffcoat
This report describes the sensitivity of different kinds of tests that detect SARS-CoV-2, the virus that causes COVID-19.

14 November 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSarah E Smith-Jeffcoat
Sarah E Smith-Jeffcoat
JBJessica E Biddle
Jessica E Biddle
HTH Keipp Talbot
H Keipp Talbot
KMKerry Grace Morrissey
Kerry Grace Morrissey
MSMelissa S Stockwell
Melissa S Stockwell
PSPhillip P Salvatore
Phillip P Salvatore
Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus disease 2019 (COVID-19); however, rebound after treatment has been reported. We compared symptom and viral dynamics in individuals with COVID-19 who completed N/R treatment and similar untreated individuals. We identified symptomatic participants who tested severe acute respiratory syndrome coronavirus 2–positive and were N/R eligible from a COVID-19 household transmission study. Index cases from ambulatory settings and their households contacts were enrolled. We collected daily symptoms, medication use, and respiratory specimens for quantitative polymerase chain reaction for 10 days during March 2022—May 2023. Participants who completed N/R treatment (treated) were propensity score matched to untreated participants. We compared symptom rebound, viral load (VL) rebound, average daily symptoms, and average daily VL by treatment status measured after N/R treatment completion or 7 days after symptom onset if untreated. Treated (n = 130) and untreated participants (n = 241) had similar baseline characteristics. After treatment completion, treated participants had greater occurrence of symptom rebound (32% vs 20%; P = .009) and VL rebound (27% vs 7%; P < .001). Average daily symptoms were lower among treated participants without symptom rebound (1.0 vs 1.6; P < .01) but not statistically lower with symptom rebound (3.0 vs 3.4; P = .5). Treated participants had lower average daily VLs without VL rebound (0.9 vs 2.6; P < .01) but not statistically lower with VL rebound (4.8 vs 5.1; P = .7). Individuals who completed N/R treatment experienced fewer symptoms and lower VL but rebound occured more often compared with untreated individuals. Providers should prescribe N/R, when indicated, and communicate rebound risk to patients.

1 June 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SSSarah E. Smith
Sarah E. Smith
JEJulia Ershova
Julia Ershova
NVNatalia Vlasova
Natalia Vlasova
ENElena Nikishova
Elena Nikishova
ITIrina Tarasova
Irina Tarasova
JCJ. Peter Cegielski
J. Peter Cegielski
Acquired resistance to antituberculosis drugs decreases effective treatment options and the likelihood of treatment success. We identified risk factors for acquisition of drug resistance during treatment for multidrug-resistant tuberculosis (MDR TB) and evaluated the effect on treatment outcomes. Data were collected prospectively from adults from Arkhangelsk Oblast, Russia, who had pulmonary MDR TB during 2005–2008. Acquisition of resistance to capreomycin and of extensively drug-resistant TB were more likely among patients who received 3 effective drugs (9.4% vs. 0% and 8.6% vs. 0.8%, respectively). Poor outcomes were more likely among patients with acquired capreomycin resistance (100% vs. 25.9%), acquired ofloxacin resistance (83.6% vs. 22.7%), or acquired extensive drug resistance (100% vs. 24.4%). To prevent acquired drug resistance and poor outcomes, baseline susceptibility to first- and second-line drugs should be determined quickly, and treatment should be adjusted to contain >3 effective drugs.

18 February 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
SSSarah E. Smith-Jeffcoat
Sarah E. Smith-Jeffcoat
MPMary A. Pomeroy
Mary A. Pomeroy
SSSadia Sleweon
Sadia Sleweon
SSSamira Sami
Samira Sami
JRJessica N. Ricaldi
Jessica N. Ricaldi
HKHannah L. Kirking
Hannah L. Kirking
This report describes an outbreak of the SARS-CoV-2 Omicron variant among people attending a convention in New York City.

18 January 2025 in Epidemics
Verified
Journal Article
Open access
LCLouis Yat Hin Chan
Louis Yat Hin Chan
SMSinead E. Morris
Sinead E. Morris
MSMelissa S. Stockwell
Melissa S. Stockwell
NBNatalie M. Bowman
Natalie M. Bowman
EAEdwin Asturias
Edwin Asturias
AMAlexandra M. Mellis
Alexandra M. Mellis
The generation time, representing the interval between infections in primary and secondary cases, is essential for understanding and predicting the transmission dynamics of seasonal influenza, including the real-time effective reproduction number (Rt). However, comprehensive generation time estimates for seasonal influenza, especially since the 2009 influenza pandemic, are lacking. We estimated the generation time utilizing data from a 7-site case-ascertained household study in the United States over two influenza seasons, 2021/2022 and 2022/2023. More than 200 individuals who tested positive for influenza and their household contacts were enrolled within 7 days of the first illness in the household. All participants were prospectively followed for 10 days, completing daily symptom diaries and collecting nasal swabs, which were then tested for influenza via RT-PCR. We analyzed these data by modifying a previously published Bayesian data augmentation approach that imputes infection times of cases to obtain both intrinsic (assuming no susceptible depletion) and realized (observed within household) generation times. We assessed the robustness of the generation time estimate by varying the incubation period, and generated estimates of the proportion of transmission occurring before symptomatic onset, the infectious period, and the latent period. We estimated a mean intrinsic generation time of 3.2 (95 % credible interval, CrI: 2.9-3.6) days, with a realized household generation time of 2.8 (95 % CrI: 2.7-3.0) days. The generation time exhibited limited sensitivity to incubation period variation. Estimates of the proportion of transmission that occurred before symptom onset, the infectious period, and the latent period were sensitive to variations in the incubation period. Our study contributes to the ongoing efforts to refine estimates of the generation time for influenza. Our estimates, derived from recent data following the COVID-19 pandemic, are consistent with previous pre-pandemic estimates, and will be incorporated into real-time Rt estimation efforts.

5 April 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JMJoLynn P Montgomery
JoLynn P Montgomery
JMJuan Luis Marquez
Juan Luis Marquez
JNJennifer Nord
Jennifer Nord
ASAleksandra R Stamper
Aleksandra R Stamper
EEElizabeth A Edwards
Elizabeth A Edwards
CHChristopher H Hsu
Christopher H Hsu
Background: Human adenoviruses (HAdVs) can cause outbreaks of flu-like illness in university settings. Most infections in healthy young adults are mild; severe illnesses rarely occur. In Fall 2022, an adenovirus outbreak was identified in university students. Methods: HAdV cases were defined as university students 17–26 years old who presented to the University Health Service or nearby emergency department with flu-like symptoms (eg, fever, cough, headache, myalgia, nausea) and had confirmed adenovirus infections by polymerase chain reaction (PCR). Demographic and clinical characteristics were abstracted from electronic medical records; clinical severity was categorized as mild, moderate, severe, or critical. We performed contact investigations among critical cases. A subset of specimens was sequenced to confirm the HAdV type. Results: From 28 September 2022 to 30 January 2023, 90 PCR-confirmed cases were identified (51% female; mean age, 19.6 years). Most cases (88.9%) had mild illness. Seven cases required hospitalization, including 2 critical cases that required intensive care. Contact investigation identified 44 close contacts; 6 (14%) were confirmed HAdV cases and 8 (18%) reported symptoms but never sought care. All typed HAdV-positive specimens (n = 36) were type 4. Conclusions: While most students with confirmed HAdV had mild illness, 7 otherwise healthy students had severe or critical illness. Between the relatively high number of hospitalizations and proportion of close contacts with symptoms who did not seek care, the true number of HAdV cases was likely higher. Our findings illustrate the need to consider a wide range of pathogens, even when other viruses are known to be circulating.